Biosimilars

Biogen tips its biosimilars to save EU payers €1.8bn in 2019

20-Jun-2019 By Nick Taylor

Biogen has predicted that its three biosimilars will save European healthcare systems €1.8bn this year.

Cel-Sci’s arthritis vaccine ‘reprogramming’ the immune system

29-May-2019 By Vassia Barba

Cel-Sci’s rheumatoid arthritis treatment, developed under an $1.5m NIH grant, will be featured at the BIO Convention in Philadelphia next week.

Celltrion plots $33.6bn investment and 1m litre production capacity expansion

20-May-2019 By Ben Hargreaves

Celltrion plans to invest across its pharmaceutical business up to 2030, creating an estimated 110,000 new jobs in the process and launching 20 products.

Boehringer ends ‘distraction’ by signing Humira biosimilar deal

15-May-2019 By Ben Hargreaves

Boehringer Ingelheim settles litigation with AbbVie over the possible introduction of its Humira biosimilar and agrees a license to market its competitor in 2023.

FDA chief frames biosimilar insulin as answer to 'intolerable' prices

15-May-2019 By Nick Taylor

Acting US FDA commissioner thinks incoming changes to the regulation of insulin may counter the ‘whopping’ price increases seen in recent years.

Allergan creates 63 jobs with biologics manufacturing expansion in Ireland

30-Apr-2019 By Ben Hargreaves

Allergan will expand its existing facilities in Ireland through an investment of €65m to produce new product formats for existing and investigational products.

Roche revises sales expectations upwards on uptake of biologics

17-Apr-2019 By Ben Hargreaves

Despite increased competition from biosimilars in Europe, Roche announces sales of its pharmaceutical divisions are up by 10%.

Alvotech provides Stelara biosimilar supply to Fuji Pharma

17-Apr-2019 By Ben Hargreaves

Fuji Pharma signs agreement to receive an exclusive supply of the ustekinumab biosimilar for the Japanese market, furthering a previous investment agreement.

Selexis’ biologic platform generates first-ever approved Soliris biosimilar

11-Apr-2019 By Maggie Lynch

First-ever Soliris biosimilar approved in Russia after it was produced through Selexis’ SureTechnology platform and cell line.

Authorities raid Korean stock exchange over Samsung BioLogics IPO

19-Mar-2019 By Ben Hargreaves

Korean authorities continue to place pressure on the CDMO, after prosecutors raided the office of the national stock exchange regarding behaviour preceding the public listing of Samsung BioLogics.

First oncology mAb biosimilar from Pfizer approved by FDA

14-Mar-2019 By Maggie Lynch

US FDA approves Pfizer’s Trazimera, a biosimilar to Roche’s blockbuster product, Herceptin, for the treatment of HER2 positive breast cancer.

Novasep and Sartorius combine forces on chromatography applications

13-Mar-2019 By Maggie Lynch

Sartorius and Novasep collaborate to bolster chromatography and single-use bioprocessing applications for efficiency and efficacy.

NEWS IN BRIEF

Sagent acquires US facility with an eye on future biosimilar products

12-Mar-2019 By Staff reporter

Sagent purchases Xellia’s FDA-approved site in North Carolina, which has capabilities to manufacture both small molecule and biologic products.

Lilly cuts insulin price 50% after congressional hearing

06-Mar-2019 By Ben Hargreaves

Lilly announces the launch of a generic version of Humalog, which will be available in the US with a list price 50% lower than the brand product.

UPDATED

Boehringer compelled to reveal Humira biosimilar launch plans

28-Feb-2019 By Ben Hargreaves

A judge has ruled in favour of AbbVie, finding that Boehringer should disclose its US launch plans for its Humira biosimilar if it wants to prove patent protection inhibited its commercial release.